Lower whole blood glutathione peroxidase (GPX) activity in depression, but not in myalgic encephalomyelitis / chronic fatigue syndrome: Another pathway that may be associated with coronary artery disease and neuroprogression in depression

Neuroendocrinology Letters

Volumn 32, Issue 2, 2011, Pages 133-140

  Maes, Michael ^a   Mihaylova, Ivanka ^a   Kubera, Marta ^b   Uytterhoeven, Marc ^c   Vrydags, Nicolas ^c   Bosmans, Eugene ^c  

^a Piyavate Hospital   (Thailand)

^b INSTITUTE OF PHARMACOLOGY   (Poland)

^c AML Laboratory   (Belgium)

Author keywords

Antioxidants; Chronic fatigue syndrome; Coronary artery disease; Cytokines; Depression; Glutathione peroxidase; Inflammation; Neuroprogression; Oxidative stress

Indexed keywords

GLUTATHIONE PEROXIDASE; HYDROPEROXIDE;

ARTICLE; AUTONOMIC NERVOUS SYSTEM; CHRONIC FATIGUE SYNDROME; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME METABOLISM; HAMILTON SCALE; HUMAN; NERVOUS SYSTEM DEVELOPMENT; OXIDATION; PROTEIN BLOOD LEVEL;

EID: 80051630646     PISSN: 0172780X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Text Revision (DSM-IV-TR), 2000; Washington DC.
2. Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Gonçalves CA, Young LT, Yatham LN (2009). 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci 34(4): 263-271.
3. Arakawa M, Ishimura A, Arai Y, Kawabe K, Suzuki S, Ishige K, Ito Y (2007). N-Acetylcysteine and ebselen but not nifedipine protected cerebellar granule neurons against 4-hydroxynonenal-induced neuronal death. Neurosci Res 57(2): 220-229. (Pubitemid 46177290)
4. Avissar N, Ornt DB, Yagil Y, Horowitz S, Watkins RH, Kerl EA, Takahashi K, Palmer IS, Cohen HJ (1994). Human kidney proximal tubules are the main source of plasma glutathione peroxidase. Am J Physiol 266(2 Pt 1): C367-375.
5. Barbaro G, Di Lorenzo G, Soldini M, Bellomo G, Belloni G, Grisorio B, Barbarini G (1997). Vagal system impairment in human immunodeficiency virus-positive patients with chronic hepatitis C: does hepatic glutathione deficiency have a pathogenetic role? Scand J Gastroenterol 32(12): 1261-1266.
6. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush Al (2008). N-acetyl cysteine for depressive symptoms in bipolar disorder - a double-blind randomized placebo-controlled trial. Biol Psychiatry 64(6): 468-475.
7. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhaes PV, Amminger P, McGorry P, Malhi GS (2011). Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3): 804-817.
8. Chambers I, Frampton J, Goldfarb P, Affara N, McBain W, Harrison PR (1986). The structure of the mouse glutathione peroxidase gene: the selenocysteine in the active site is encoded by the 'termination' codon, TGA. EMBO J 5(6): 1221-1227.
9. Chu FF, Esworthy RS, Doroshow JH, Doan K, Liu XF (1992). Expression of plasma glutathione peroxidase in human liver in addition to kidney, heart, lung, and breast in humans and rodents. Blood 79(12): 3233-3238.
10. Eren I, Naziroǧglu M, Demirdaşs A (2007a). Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 32(7): 1188-1195.
11. Eren I, Nazirogglu M, Demirdaşs A, Celik O, Uǧguz AC, Altunbaşsak A, Ozmen I, Uz E (2007b). Venlafaxine modulates depression-induced oxidative stress in brain and medulla of rat. Neurochem Res 32(3): 497-505. (Pubitemid 46295149)
12. Flohé L (1978). Glutathione peroxidase: fact and fiction. Ciba Found Symp 65: 95-122.
13. Forlenza MJ, Miller GE (2006). Increased serum levels of 8-hydroxy-2′-deoxyguanosine in clinical depression. Psychosomatic Med. 68(1): 1-7. (Pubitemid 43803209)
14. Fukuda K, Straus SE, Hickie I, Sharpe MC, Dobbins JG, Komaroff A (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann Intern Med 121(12): 953-959.
15. Fulle S, Mecocci P, Fanó G, Vecchiet I, Vecchini A, Racciotti D, Cherubini A, Pizzigallo E, Vecchiet L, Senin U, Beal MF (2000). Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med 29(12): 1252-1259.
16. Gałlecki P, Szemraj J, Bieńnkiewicz M, Florkowski A, Gałlecka E (2009). Lipid peroxidation and antioxidant protection in patients during acute depressive episodes and in remission after fluoxetine treatment. Pharmacol Rep 61(3): 436-447.
17. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-61.
18. He M, Xing S, Yang B, Zhao L, Hua H, Liang Z, Zhou W, Zeng J, Pei Z (2007). Ebselen attenuates oxidative DNA damage and enhances its repair activity in the thalamus after focal cortical infarction in hypertensive rats. Brain Res 1181: 83-92. (Pubitemid 350050915)
19. Herbette S, Roeckel-Drevet P, Drevet JR (2007). Seleno-independent glutathione peroxidases. More than simple antioxidant scavengers. FEBS J 274(9): 2163-2180.
20. Jammes Y, Steinberg JG, Mambrini O, Bregeon F, Delliaux S (2005). Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J Intern Med 257(3): 299-310. (Pubitemid 40342133)
21. Jean Harry G, Bruccoleri A, Lefebvre d'Hellencourt C (2003). Differential modulation of hippocampal chemical-induced injury response by ebselen, pentoxifylline, and TNFalpha-, IL-1alpha-, and IL-6-neutralizing antibodies. J Neurosci Res 73(4): 526-536.
22. Johnsen-Soriano S, Bosch-Morell F, Miranda M, Asensio S, Barcia JM, Roma J, Monfort P, Felipo V, Romero FJ (2007). Ebselen prevents chronic alcohol-induced rat hippocampal stress and functional impairment. Alcohol Clin Exp Res 31(3): 486-492. (Pubitemid 46239282)
23. Joseph M (1995). The generation of free radicals by blood platelets. In Immunology of Platelets (Joseph M, ed). Academic Press, London-Toronto: 209-225.
24. József L, Filep JG (2003). Selenium-containing compounds attenuate peroxynitrite-mediated NF-kappaB and AP-1 activation and interleukin-8 gene and protein expression in human leukocytes. Free Radic Biol Med 35(9): 1018-1027. (Pubitemid 37315695)
25. Kennedy BP, Rao F, Botiglieri T, Sharma S, Lillie EO, Ziegler MG, O'connor DT (2005a). Contributions of the sympathetic nervous system, glutathione, body mass and gender to blood pressure increase with normal aging: influence of heredity. J Hum Hypertens 19(12): 951-969.
26. Kennedy G, Spence VA, McLaren M, Hill A, Underwood C, Belch JJ (2005b). Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic Biol Med 39(5): 584-589. (Pubitemid 41112100)
27. Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003). Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8(6): 365-370. (Pubitemid 38128544)
28. Kodydková J, Vávrová L, Zeman M, Jirák R, Macášek J, Staňnková B, Tvrzická E, Zák A (2009). Antioxidative enzymes and increased oxidative stress in depressive women. Clin Biochem 42(13-14): 1368-1374.
29. Lee YJ, Choi B, Lee EH, Choi KS, Sohn S (2006). Immobilization stress induces cell death through production of reactive oxygen species in the mouse cerebral cortex. Neurosci Lett 392(1-2): 27-31. (Pubitemid 41757570)
30. Lei XG (2002). In vivo antioxidant role of glutathione peroxidase: evidence from knockout mice. Methods Enzymol 347: 213-225.
31. Li Y, Cao Z (2002). The neuroprotectant ebselen inhibits oxidative DNA damage induced by dopamine in the presence of copper ions. Neurosci Lett 330(1): 69-73. (Pubitemid 35245772)
32. Maes M (2008). The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29(3): 287-291.
33. Maes M (2009). Inflammatory and oxidative & nitrosative stress (IO&NS) pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 22(1): 75-83.
34. Maes M. An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Jul 4. [Epub ahead of print] PubMed PMlD: 20609377.
35. Maes M (2011). Nooit meer moe: CVS ontmaskerd. Zorro Uitgevers, Damme.
36. Maes M, Meltzer HYM (1995). The serotonin hypothesis of major depression. In: F.Bloom and D.Kupfer (Eds.), Psychopharmacology, the Fourth Generation of Progress (eds.). Raven Press, New York, pp 933-941.
37. Maes M, Meltzer HY, Suy E, Minner B, Calabrese J, Cosyns P (1993). Sleep disorders and anxiety as symptom profiles of sympathoadrenal system hyperactivity in major depression. J Affect Disord 27(3): 197-207. (Pubitemid 23080337)
38. Maes M, Meltzer HY, Cosyns P, Schotte C (1994). Evidence for the existence of major depression with and without anxiety features. Psychopathol 27: 1-13. (Pubitemid 24194126)
39. Maes M, Vandoolaeghe E, Neels H, Demedts P, Wauters A, Meltzer HY, Altamura C, Desnyder R (1997). Lower serum zinc in major depression is a sensitive marker of treatment resistance and of the immune/inflammatory response in that illness. Biol Psychiatry 42(5): 349-358. (Pubitemid 27380969)
40. Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000). Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58(3): 241-246.
41. Maes M, Mihaylova I, De Ruyter M (2005). Decreased dehydroepiandrosterone sulfate but normal insulin-like growth factor in chronic fatigue syndrome (CFS): relevance for the inflammatory response in CFS. Neuro Endocrinol Lett 26(5): 487-492. (Pubitemid 43013719)
42. Maes M, Mihaylova I, De Ruyter M (2006a). Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J Affect Disord 90(2-3): 141-147. (Pubitemid 43183522)
43. Maes M, Mihaylova I, Leunis JC (2006b). Chronic fatigue syndrome is accompanied by an IgM-related immune response directed against neopitopes formed by oxidative or nitrosative damage to lipids and proteins. Neuro Endocrinol Lett 27(5): 615-621.
44. Maes M, Mihaylova I, Bosmans E (2007a). Not in the mind of neurasthenic lazybones but in the cell nucleus: patients with chronic fatigue syndrome have increased production of nuclear factor kappa beta. Neuro Endocrinol Lett 28(4): 456-462. (Pubitemid 47577726)
45. Maes M, Mihaylova I, Kubera M, Bosmans E (2007b). Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro Endocrinol Lett 28(4): 463-469. (Pubitemid 47577727)
46. Maes M, Mihaylova I, Leunis JC (2007c). Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 28(6): 861-867.
47. Maes M, Mihaylova I, Kubera M, Leunis JC (2008). An IgM-mediated immune response directed against nitro-bovine serum albumin (nitro-BSA) in chronic fatigue syndrome (CFS) and major depression: evidence that nitrosative stress is another factor underpinning the comorbidity between major depression and CFS. Neuro Endocrinol Lett 29(3): 313-319.
48. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009a). Coenzyme Q10 deficiency in myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro Endocrinol Lett 30(4): 470-476.
49. Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009b). Lower plasma Coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocinol Lett 30(4): 462-469.
50. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B, Maj M (2009c). The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1): 27-53.
51. Maes M, Ruckoanich P, Chang YS, Mahanonda N, Berk M (2010). Multiple aberrations in shared inflammatory and oxidative & nitrosative stress (IO&NS) pathways explain the co-association of depression and cardiovascular disorder (CVD), and the increased risk for CVD and due mortality in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. Jun 16. [Epub ahead of print] PubMed PMID: 20561554.
52. Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, Gardner A, Ruckoanich P, Geffard M, Altamura C, Galecki P, Berk M (2011). Editorial: (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: From antioxidants to kinase inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2011 Mar 2. [Epub ahead of print] PubMed PMID: 21376099.
53. Mannervik B. The enzymes of glutathione metabolism: an overview (1987). Biochem Soc Trans 15(4): 717-718.
54. Margis R, Dunand C, Teixeira FK, Margis-Pinheiro M (2008). Glutathione peroxidase family - an evolutionary overview. FEBS J 275(15): 3959-3970. (Pubitemid 351990959)
55. Meister A (1988). Glutathione metabolism and its selective modification. J Biol Chem 263(33): 17205-17208.
56. Mercanoglu G, Safran N, Uzun H, Eroglu L (2008). Chronic emotional stress exposure increases infarct size in rats: the role of oxidative and nitrosative damage in response to sympathetic hyperactivity. Methods Find Exp Clin Pharmacol 30(10): 745-752.
57. Mill GC (1957). Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown". J Biol Chem 229(1): 189-197.
58. Müller A, Cadenas E, Graf P, Sies H (1984). A novel biologically active seleno-organic compound - I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochem Pharmacol 33(20): 3235-3239.
59. Murakami E, Iwata T, Hiwada K, Kokubu T (1987). Brain glutathione and blood pressure control. J Cardiovasc Pharmacol 10 Suppl 12: S112-115.
60. Owen AJ, Batterham MJ, Probst YC, Grenyer BF, Tapsell LC (2005). Low plasma vitamin E levels in major depression: diet or disease? Eur J Clin Nutr 59(2): 304-306. (Pubitemid 40268328)
61. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004). Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19(2): 89-95. (Pubitemid 38316767)
62. Paglia DE, Valentine WN (1967). Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70(1 ): 158-169.
63. Pal SN, Dandiya PC (1994). Glutathione as a cerebral substrate in depressive behavior. Pharmacol Biochem Behav 48(4): 845-851. (Pubitemid 24259812)
64. Porciúncula LO, Rocha JB, Cimarosti H, Vinadé L, Ghisleni G, Salbego CG, Souza DO (2003). Neuroprotective effect of ebselen on rat hippocampal slices submitted to oxygen-glucose deprivation: correlation with immunocontent of inducible nitric oxide synthase. Neurosci Lett 346(1-2): 101-104. (Pubitemid 36792203)
65. Porciúncula LO, Rocha JB, Ghisleni G, Tavares RG, Souza DO (2004). The effects of ebselen on [3H]glutamate uptake by synaptic vesicles from rat brain. Brain Res 1027(1-2): 192-195. (Pubitemid 39371009)
66. Posser T, Kaster MP, Barauna SC, Rocha JB, Rodrigues AL, Leal RB (2009). Antidepressant-like effect of the organoselenium compound ebselen in mice: evidence for the involvement of the monoaminergic system. Eur J Pharmacol 602(1): 85-91.
67. Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S (2007). Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22(2): 67-73. (Pubitemid 46505714)
68. Satoh T, Ishige K, Sagara Y (2004). Protective effects on neuronal cells of mouse afforded by ebselen against oxidative stress at multiple steps. Neurosci Lett 371(1): 1-5. (Pubitemid 39410504)
69. Seo JY, Lee CH, Cho JH, Choi JH, Yoo KY, Kim DW, Park OK, Li H, Choi SY, Hwang IK, Won MH. (2009). Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. J Neurol Sci 285: 88-94.
70. Smirnova IV, Pall ML (2003). Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol Cell Biochem 248(1-2): 93-95. (Pubitemid 36833645)
71. Song C, Killeen AA, Leonard BE (1994). Catalase, superoxide dismutase and glutathione peroxidase activity in neutrophils of sham-operated and olfactory-bulbectomised rats following chronic treatment with desipramine and lithium chloride. Neuropsychobiology 30(1): 24-28. (Pubitemid 24211369)
72. Srivastava N, Barthwal MK, Dalai PK, Agarwal AK, Nag D, Seth PK, Srimal RC, Dikshit M (2002). A study on nitric oxide, beta-adrenergic receptors and antioxidant status in the polymorphonuclear leukocytes from the patients of depression. J Affect Disord 72(1): 45-52. (Pubitemid 35232163)
73. Takahashi K, Akasaka M, Yamamoto Y, Kobayashi C, Mizoguchi J, Koyama J (1990). Primary structure of human plasma glutathione peroxidase deduced from cDNA sequences. J Biochem 108(2): 145-148. (Pubitemid 20234496)
74. Thase ME, Rush AJ (1995). Treatment-resistant depression. In Bloom FE, Kupfer DJ (eds), Psychopharmacology, the Fourth Generation of Progress. New York: Raven Press, pp 1081-1098.
75. Ursini F, Bindoli A (1987). The role of selenium peroxidases in the protection against oxidative damage of membranes. Chem Phys Lipids 44(2-4): 255-276. (Pubitemid 17146547)
76. Van Hunsel F, Wauters A, Vandoolaeghe E, Neels H, Demedts P, Maes M (1996). Lower total serum protein, albumin, and beta- and gamma-globulin in major and treatment-resistant depression: effects of antidepressant treatments. Psychiatr Res 20: 159-169. (Pubitemid 27072581)
77. Vecchiet J, Cipollone F, Falasca K, Mezzetti A, Pizzigallo E, Bucciarelli T, De Laurentis S, Affaitati G, De Cesare D, Giamberardino MA (2003). Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci Lett 335(3): 151-154. (Pubitemid 36071622)
78. Voetsch B, Jin RC, Bierl C, Benke KS, Kenet G, Simioni P, Ottaviano F, Damasceno BP, Annichino-Bizacchi JM, Handy DE, Loscalzo J (2007). Promoter polymorphisms in the plasma glutathione peroxidase (GPx-3) gene: a novel risk factor for arterial ischemic stroke among young adults and children. Stroke 38(1): 41-49. (Pubitemid 46035604)
79. Whitin JC, Bhamre S, Tham DM, Cohen HJ (2002). Extracellular glutathione peroxidase is secreted basolaterally by human renal proximal tubule cells. Am J Physiol Renal Physiol 283(1 ): F20-28.
80. Yoshizumi M, Fujita Y, Izawa Y, Suzaki Y, Kyaw M, Ali N, Tsuchiya K, Kagami S, Yano S, Sone S, Tamaki T (2004). Ebselen inhibits tumor necrosis factor-alpha-induced c-Jun N-terminal kinase activation and adhesion molecule expression in endothelial cells. Exp Cell Res 292(1): 1-10. (Pubitemid 38058258)
81. Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002). A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 52(6): 501-509. (Pubitemid 34759879)
82. Zhou FL, Zhang WG, Su ZX, Meng X, Tian W (2006). Relationship between oxidative stress and depression in patients with acute leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 14(5): 872-875.
83. Zweig MH, Campbell G (1993). Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39: 561-577. (Pubitemid 23118304)